Tokyo, Nov. 10 -- UMIN Clinical Trials Registry (UMIN-CTR) received information related to the study (UMIN000063575) titled 'Real-World Incidence and Risk Factors of TARLAtamab-Associated Pneumonitis: A Multicenter Retrospective AnalysIS Focusing on Comorbid Interstitial Pneumonia' on Nov. 10.
Study Type:
Observational
Primary Sponsor:
Institute - Kansai Medical University
Condition:
Condition - Small cell lung cancer previously treated with at least one regimen of chemotherapy, including a platinum doublet, who received tarlatamab in real-world clinical practice.
Classification by malignancy - Malignancy
Genomic information - NO
Objective:
Narrative objectives1 - To clarify the incidence and severity of tarlatamab-induced pneumonitis ...